Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
April 07 2021 - 8:00AM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), announced today it will be presenting a poster at the
upcoming American Association for Cancer Research (AACR) Virtual
2021 Annual Meeting.
The poster highlights work evaluating the
ability of the non-viral Sleeping Beauty transposon/transposase
gene transfer system to re-direct the specificity of T cells
towards p53 and KRAS neoantigens and characterizing the resultant
engineered TCR-T cell populations for specificity and function.
The poster is entitled “Hotspot mutations in
KRAS and TP53 targeted by TCR-T cells genetically modified with the
Sleeping Beauty transposon/transposase system.”
The work summarized in the poster demonstrates
that multiple TCRs with unique specificities targeting recurrent
p53 and KRAS substitutions in frequent HLA haplotypes could be
stably expressed using Sleeping Beauty transposition to re-direct
peripheral blood T cells towards tumor cells.
Dr. Raffaele Baffa, MD, PhD, Chief Medical
Officer of Ziopharm said, “We are pleased to share this update on
our TCR-T directed work with the scientific community. The Company
is working tirelessly on our Phase I/II clinical study for our
TCR-T Library, and the work presented in this poster provides us
with increased confidence in the scientific rationale behind the
trial.”
The poster will be presented as part of Session
PO.IM02.01 - Adoptive Cell Therapy. The abstract for the poster can
be found on the AACR website using this link. The poster will be
available for conference participants beginning at 8:30am ET on
Saturday, April 10, 2021 and will also be posted on the Ziopharm
Oncology website in the Investors section, using this link.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with cancer each
year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology. Ziopharm’s pipeline is built for commercially
scalable, cost effective T-cell receptor T-cell therapies based on
its non-viral Sleeping Beauty gene transfer platform, a
rapidly manufactured Sleeping Beauty-enabled CD19-specific
CAR-T program, and a precisely controlled IL-12 gene therapy. The
Company has clinical and strategic collaborations with
the National Cancer Institute, The University of Texas MD
Anderson Cancer Center and Regeneron Pharmaceuticals. For more
information, please visit www.ziopharm.com.
Investor Relations Contact:Adam D. Levy, Ph.D.,
MBAEVP, Investor Relations and Corporate CommunicationsT:
508.552.9255E: alevy@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2023 to Apr 2024